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Accumulating evidences have suggested the existence of breast cancer stem cells
(BCSCs), which possess the potential of both self-renewal and differentiation. The
origin of BCSCs might have relationship to the development of normal mammary
stem cells. BCSCs are believed to play a key role in the initiation, recurrence and
chemo-/radiotherapy resistances of breast cancer. Therefore, elimination of BCSCs is
crucial for breast cancer therapy. However, conventional chemo and radiation therapies
cannot eradicate BCSCs effectively. Fortunately, nanotechnology holds great potential
for specific and efficient anti-BCSCs treatment. “Smart” nanocarriers can distinguish
BCSCs from the other breast cancer cells and selectively deliver therapeutic agents
to the BCSCs. Emerging findings suggest that BCSCs in breast cancer could be
successfully inhibited and even eradicated by functionalized nanomedicines. In this
review, we focus on origin of BCSCs, strategies used to target BCSCs, and summarize
the nanotechnology-based delivery systems that have been applied for eliminating
BCSCs in breast cancer.
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INTRODUCTION
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death
among females worldwide, accountings for 25% of all cancer cases and 15% of all cancer deaths
among females (Torre et al., 2015). Accumulating evidence indicates that the local recurrent
and/or distant metastatic tumors, the major causes of lethality in the clinic, are related to the
aggressive phenotype of a small fraction of cancer cells loosely termed as cancer stem cells (CSCs),
tumor initiating cells (TICs), or cancer metastasis-initiating cells (CMICs) (Geng et al., 2014).
Breast cancer stem cells (BCSCs) were isolated and identified initially by Al-Hajj’s group (Al-
Hajj et al., 2003). Since then, it has been revealed that BCSCs play a key role in not only the
original tumorigenicity but also the local invasion and migration propensity of the breast cancer
cells (Clarke, 2005; Moncharmont et al., 2012; Chen et al., 2013). BCSCs are shown to exhibit
unique growth resilience, including the capacity for self-renewal, differentiation potential, and
resistance to most anti-cancer agents including chemo and/or radiotherapy, all of which are
believed to contribute to the development and overall aggressiveness of the recurrent or metastatic
lesions (Geng et al., 2014). Moreover, the drug resistance of tumor seems to be correlated with
some properties of CSCs, such as ability of DNA repairing and overexpression of drug eﬄux
transporters and antiapoptotic proteins (Vinogradov and Wei, 2012). Therefore, the stem cell
model of mammary tumorigenesis has important clinical implications for the treatment of breast
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cancer. The development of new therapeutic strategies designed
to target BCSCs may ultimately result in more effective
interventions for the treatment of breast cancer (Dontu et al.,
2003).
An increasing number of therapeutic agents that have effects
on eliminating or inhibiting BCSCs have been proposed and
confirmed, such as salinomycin (Muntimadugu et al., 2016),
disulfiram (Yip et al., 2011), chloroquine (Liang et al., 2016),
curcumin (Gülçür et al., 2013), and siRNA (Zuo et al.,
2016). However, most of these agents have characteristics
limiting their effective applications in vivo, including poor
solubility, off-target effects, instability, short circulation half-
life, undesirable biodistribution and low therapeutic indices (Hu
et al., 2012). Therefore, the development of BCSCs-targeting
drug/gene delivery systems is desirable to optimize anti-BCSCs
therapies.
Nanotechnology has shown immense potential for cancer
detection, prevention, and treatment. Nanomedicines have
revolutionalized drug delivery, allowing for therapeutic agents
to selectively targeting tumor tissue and cancer cells, while
minimizing toxicity to normal cells (Gao et al., 2014).
Nanocarriers are ideal platform for successful BCSCs-specific
therapies because they possess the properties of high drug loading
capacity, solubility enhancement effects, site-specific delivery
mechanism that avoids drug deposition in normal cells and
tissues, negligible release of drug prematurely, and controlled
release mechanism that provides effective drug doses to the target
site (Estanqueiro et al., 2015). A wide range of nanocarriers (e.g.,
polymeric nanoparticles, metal nanoparticles, polymeric micelles,
liposomes, and carbon nanotubes) has demonstrated significant
potential in CSCs-targeted delivery (Shen et al., 2016). However,
the application of nanotechnology specifically to develop BCSCs-
targeted therapies is still fraught with challenges and barriers,
with many issues remaining unresolved. In this review, we briefly
discuss the origin and properties of BCSCs, and provide a
summary of the latest developments in nanomedicine approaches
for BCSCs-targeted therapy in recent literature.
BCSCs THEORY
Mammary Stem Cells and Origin of
BCSCs
The mammary gland is a unique organ that undergoes extensive
remodeling and differentiation even in adults (Polyak, 2007).
It exhibits unique developmental features during puberty,
pregnancy and lactation. For each round of pregnancy, the
mammary gland undergoes sequential cycles of proliferation,
differentiation and apoptosis, while alveolar ducts form and grow,
differentiate to produce milk and, after lactation, cease, revert and
regress to the pre-pregnancy state (Williams et al., 2009). All of
these suggest the presence of mammary stem cells as the basis for
the capacity of renewal (Williams et al., 2009). The existence of
stem-like cells in normal breast tissue has been proven by several
studies (Dontu et al., 2003, 2004; Liu et al., 2005). These cells
are undifferentiated cells, which posses the ability of self-renewal,
and can differentiate into alveolar epithelial cells, ductal epithelial
cells, and myoepithelial cells (Wicha et al., 2003). Mammary stem
cells also demonstrated a significant genes expression overlap
with embryonic, neuronal, and hematopoietic stem cells (Wicha
et al., 2003).
The origin of BCSCs is still being debated (Figure 1).
A hypothesis that has gained considerable interests in recent
years postulates that the BCSCs may be derived from normal
mammary stem cells transformed by the deregulation of normal
self-renewal (Dontu et al., 2003, 2004). It was found that normal
mammary stem cells and BCSCs share many characteristics,
such as telomerase expression, self-renewal ability, differentiation
capability, apoptosis resistance, as well as ability to home
to specific sites (Dontu et al., 2003; Wicha et al., 2003).
Stem cells have the machinery to activate self-renewal and
therefore may require fewer mutations to maintain it than
more differentiated cells would need to activate it ectopically
(Passegué et al., 2003). In addition, mammary stem cells persist
much longer and therefore have much greater opportunities
FIGURE 1 | Mammary stem cells and origin of BCSCs. BCSCs may be derived from transformation of mammary stem cell. Alternatively, BCSCs may arise from
differentiated cancer cells through an unknown mechanism.
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to accumulate mutations than more differentiated cells. Those
accumulated mutations may cause the normal stem cell to
gradually change into BCSCs. Another hypothesis suggests that
BCSCs may be derived from differentiated cells (Lu et al.,
2016), but the mechanism is still uncertain. Guo et al. (2012)
found that transient coexpression of exogenous Slug and Sox9
sufficed to convert differentiated luminal cells into mammary
stem cells with long-term mammary gland-reconstituting ability,
which also promoted the tumorigenic and metastasis-seeding
abilities of human breast cancer cells. This hypothesis was also
supported by Koren et al. (2015) findings that the expression of
PIK3CAH1047R in lineage-committed basal Lgr5-positive and
luminal keratin-8-positive cells of the adult mouse mammary
gland evoked cells to dedifferentiate into a multipotent stem-like
state.
Microenvironment of BCSCs
Just as normal stem cells are regulated by their
microenvironment, or niche, BCSCs interact with and are
regulated by the factors in their microenvironment. These
factors include fibroblast stimuli, immune cells, autocrine
signals, and extracellular matrix (ECM) components, as well
as physical/chemical factors such as oxygen pressure, nutrients
levels, and pH (Bozorgi et al., 2015). Growth factors and cytokines
released by tumor cells and cancer-associated fibroblasts and
immune cells have strong effects on the survival and metastasis
of BCSCs (Korkaya et al., 2011; Bozorgi et al., 2015; Brooks and
Wicha, 2015). Korkaya et al. (2012) found the activation of an
interleukin-6(IL-6) inflammatory loop mediated trastuzumab
resistance in HER2+ breast cancer by expanding the cancer
stem cell population. Ginestier et al. (2010) revealed that CXCR1
blockade selectively targeted human BCSCs and prevented
tumor formation in vitro and in xenografts. Moreover, chronic
exposure of epithelial cells to high levels of bone morphogenetic
protein 2 (BMP2) has recently been demonstrated to initiate
stem cell transformation toward a luminal tumor-like phenotype
(Chapellier and Maguer-Satta, 2016). Carcinogen-driven
deregulation of the stem cell niche could therefore represent a
driving force to promote transformation and dictate the ultimate
breast tumor subtype (Chapellier and Maguer-Satta, 2016),
which in turn suggests that the BCSCs niche is a potential target
for anticancer therapy. This strategy has yet to be sufficiently
explored (LaBarge, 2010).
Phenotyping of BCSCs and Marker
The first report of isolation and identification of BCSCs was by
Al-Hajj et al. (2003), who designated them as CD44+CD24−/low
lineage−. When xenotransplanted into mice, 1000s of these
cells were enough for the initiation of tumors, while for the
unsorted population, about 50,000 cells were needed (Carrasco
et al., 2014). CD44+/CD24−/low cells have evident stem cell
features. Ponti et al. (2005) isolated and propagated BCSCs from
breast carcinoma cell line and breast cancer lesions. The cultured
cells were named CD44+/CD24− and Cx43−, and found to
overexpress the neoangiogenic and cytoprotective factors, the
putative stem cell marker Oct-4, and gave rise to new tumors
with as few as 103 cells injected into the mammary fat pad
of SCID mice. The CD44 was positively associated with stem
cell-like characteristics and the CD24 expression was related to
differentiate epithelial features (Park et al., 2010).
Expression of CD133 (Prominin-1), which is a 120 kDa
glycoprotein that localizes to plasma membrane (Mizrak et al.,
2008), is used as a marker to identify TICs or BCSCs in breast
tumors (Meyer et al., 2010). CD133+ tumor cells could form
complete tumors, and CD133 expression was proved to be closely
related to tumor size, recurrence, metastasis, clinical stage and
overall survival in breast cancer patients (Zhao et al., 2011;
Aomatsu et al., 2012). Also, in vitro and xenotransplantation
assays revealed that CD133+ cancer cells have enhanced tumor
initiating ability and drug resistant phenotype (Zobalova et al.,
2008; Mine et al., 2009; Wang et al., 2010; Swaminathan et al.,
2013).
Aldehyde dehydrogenase (ALDH) has been described as a
marker of both normal and malignant breast stem/progenitor
cells (Ginestier et al., 2007; Ricardo et al., 2011). ALDH converts
retinol to retinoic acid, and is a putative enzyme having important
properties in differentiation pathways in normal as well as cancer
stem cells (Lohberger et al., 2012; Kesharwani et al., 2015). ALDH
overexpression has been correlated with increased tumorigenesis
in comparison to CD 44+ cells alone, indicating ALDH as a
specific marker of BCSCs in breast cancers (Vira et al., 2012).
ALDH1A1 is an isoform of ALDH used in targeting BCSC and
it has been found to be responsible for chemo- and radiotherapy-
resistance (Keysar and Jimeno, 2010; Subramaniam et al., 2010;
Croker and Allan, 2012).
ENGINEERED NANOMEDICINES
TARGETED TO BCSCs
Nanotechnology nowadays offers novel solutions in cancer
therapy by enabling the engineered nanomedicines to navigate
the body in very specific ways (Kievit and Zhang, 2011).
Nanomedicines can solve the problems of drug solubility,
instability, and short circulation half-life, and can co-deliver
different drugs specifically to the target site. Due to enhanced
permeability and retention (EPR) effect, nanotechnology-based
drug delivery systems can passively accumulate at the tumor
site. Modification of the nanocarriers surface with targeting
moieties could generate enhanced specificity and cellular uptake
in target cells (Zhao et al., 2013; Aires et al., 2016; Zuo et al.,
2016). By careful control of sizes, components and targeting
moieties, nanomedicines could be specifically targeted to BCSCs
(Figure 2).
Active Targeting Strategies for Anti
BCSCs Therapy
Biological functionalization of the nanocarriers is promising
strategy for improving selectivity of delivery systems toward
specific cell types (Aires et al., 2016). In most cases, the delivery
systems are equipped with certain agents that recognize and bind
to the surface markers of BCSCs (Table 1).
The receptor CD44 is strongly expressed by the BCSCs and it is
a signaling platform that integrates cellular microenvironmental
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FIGURE 2 | Various approaches explored to target BCSCs using nanomedicines. Different nanocarriers, such as polymeric nanoparticle, inorganic
nanoparticle, micelle, liposome, nanogel, and nanotube, are developed for effective and specific drug/gene delivery to BCSCs. Strategies for improving anti-BCSCs
therapeutic efficacy include but are not limited to: (A) Nanomedicines passively accumulating at the tumor site due to EPR effect. (B) Enhanced uptake of
functionalized nanomedicines by BCSCs via receptor-mediated endocytosis. (C) Co-delivery of drugs targeting simultaneously BCSCs and bulk breast cancer cells.
(D) Metallic or metal oxide nanoparticles and carbon nanotube mediated thermal therapy provides strategy for efficient inhibition of BCSCs.
TABLE 1 | Targeting moieties for active BCSCs targeting.
Targeting moieties Targets Therapeutic agents Delivery systems Reference
Anti-CD44 antibody CD44 receptor Paclitaxel (PLGA-co-PEG) polymeric micelles Gener et al., 2015
Anti-CD44 antibody CD44 receptor Gemcitabine derivatives Iron oxide magnetic nanoparticles Aires et al., 2016




Wei et al., 2013
Hyaluronic acid CD44 receptor Salinomycin PLGA nanoparticles Muntimadugu et al., 2016
Hyaluronic acid CD44 receptor 8-hydroxyquinoline Mesoporous silica nanoparticles-supported
lipid bilayers
Wang et al., 2013
Hyaluronic acid CD44 receptor siRNA Hyaluronic acid based versatile self-assembling
nanosystems
Ganesh et al., 2013
Oligosaccharides of
hyaluronan
CD44 receptor Curcumin/paclitaxel Inorganic calcium and phosphate ions coated
hyaluronan oligosaccharides
-histidine-menthone 1,2-glycerol ketal micelles
Chen et al., 2015
Chitosan CD44 receptor Doxorubicin Pluronic F127-Chitosan nanoparticles Rao et al., 2015





Curcumin Sterically stabilized phospholipid nanomicelles Gülçür et al., 2013
Herceptin Human epidermal growth factor
receptor type 2
Salinomycin PLGA nanoparticles Aydın, 2013
cues with growth factor and cytokine signals (Lu et al.,
2016), which often chosen to be the receptor for BCSCs
targeting nanosystems. Gener et al. (2015) developed anti-
CD44 antibodies functionalized and paclitaxel (PTX) loaded
poly[(D,L-lactide-co-glycolide)-co-PEG] (PLGA-co-PEG)
micelles, which effectively promoted the internalization of PTX
in BCSCs. Aires et al. (2016) reported gemcitabine derivatives
loaded multifunctionalized iron oxide magnetic nanoparticles
(MNPs), which were modified with anti-CD44 antibody for
CD44+ cancer cells specific treatment. The targeting of these
nanoparticles to different CD44+ cancer cell lines including
breast cancer stem-like cells was observed, and the potential of
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selective drug delivery was proven by the suppression of CD44+
cancer cells in pancreatic and breast cancers cell lines.
Hyaluronic acid (HA) has been reported as a ligand that can
specifically bind to CD44 (Shen et al., 2016). Breast cancer cells
are known to have greater uptake of HA than normal tissues,
requiring HA for high P-gp expression, which contributes to
multi-drug resistance (Götte and Yip, 2006). This makes HA
an attractive targeting moiety in anti-BCSCs nanomedicines.
Wei et al. (2013) developed cholesteryl-hyaluronic acid (CHA)
nanogel-drug conjugates for efficient treatment of cancer
cells and, especially, drug-resistant and CD44-expressing
breast cancer stem-like cells. These nanogels were efficiently
internalized via CD44 receptor-mediated endocytosis and
interacted with the cancer cell membrane simultaneously.
Functionalization with HA coating also improved the cellular
uptake of salinomycin (SLM) nanoparticles by 1.5 folds
(Muntimadugu et al., 2016). Wang et al. (2013) prepared a
HA-mediated BCSCs targeting delivery system comprising of
8-hydroxyquinoline-loaded hyaluronan modified mesoporous
silica nanoparticles (MSN)-supported lipid bilayers (HA-MSS).
Their studies also showed that HA promoted the uptake of
HA-MSS in BCSCs. Ganesh et al. (2013) developed a series
of CD44-targeting HA-based self-assembling nanosystems for
siRNA delivery and observed enhanced delivery efficiency and
gene silencing activity of the siRNA in drug-resistant CD44
receptor-overexpressing tumor models. They found that several
HA derivatives could transfect siRNAs into cancer cells that
overexpressed the CD44 receptors. Free excess soluble HA
could block the CD44 receptors, which consequently resulted
in more than 90% inhibition of the cell uptake (Ganesh et al.,
2013). Chen et al. (2015) prepared novel multifunctionalized
hyaluronan oligosaccharides-histidine-menthone 1,2-glycerol
ketal (oHM) conjugates for BCSCs targeting. The oHM
conjugates, which were applied to form micelles, possess
hyaluronan oligosaccharides as the target of CD44 receptor on
BCSCs.
The chemical structure of chitosan partially resembles that of
HA, except it is positively charged, which may make chitosan-
modified nanoparticles bind more efficiently to mammalian cells.
Therefore, Rao et al. (2015) constructed a kind of chitosan-
decorated and doxorubicin-loaded polymeric nanoparticle that
specifically targeted the CD44 receptors of BCSCs. This targeting
nanoparticle increased the efficacy of doxorubicin for eliminating
BCSCs by six times compared with free drug.
Choosing CD133 as the target receptor, Swaminathan et al.
(2013) developed paclitaxel loaded and anti-CD133 antibody
modified polymeric nanoparticles. Studies demonstrated that
these nanoparticles efficiently eliminated BCSCs in vitro and
significantly inhibited tumor-regrowth in vivo, which suggested
CD133 might be a potential target for anti-BCSCs therapies.
Besides CD44 and CD133 receptors, some other targets could
also be chosen for actively targeting the BCSCs. For example,
there is a significantly higher level of vasoactive intestinal peptide
(VIP) receptor expression in the BCSC population as compared
to the bulk cancer cells, which makes the VIP a potential active
targeting moiety to achieve high anti-BCSC activity (Gülçür
et al., 2013). A novel sterically stabilized curcumin phospholipid
nanomicelles (C-SSM) delivery platform surface conjugated with
VIP has been found to successfully hinder the growth of breast
cancer with BCSCs (Gülçür et al., 2013). Aydın (2013) applied
Herceptin (HER) as the targeting ligand for salinomycin (SAL)-
loaded PLGA nanoparticles in order to enhance the binding and
accumulation of SAL in the breast cancer cells. HER is approved
as an antibody for the treatment of human epidermal growth
factor receptor type 2 (HER2)-positive metastatic breast cancers,
and the receptor is overexpressed in 25–30% of invasive breast
cancers. Since SAL can selectively deplete human BCSCs from
tumorspheres and inhibit breast cancer growth, targeting SAL to
the breast cancer bulk could lead to effective reduction of BCSCs.
Nanoparticles for BCSCs Detection and
Labeling
Although the BCSCs play critical roles in development
and recurrence of breast cancer, they represent a minor
subpopulation (2%) of the unfractionated breast cancer cells
(Dick, 2003), making it difficult to isolate, detect and label
them. Yet the detection and labeling of BCSCs is important in
building a strong clinical foundation to further explore ways
for the diagnosis and treatment of breast cancer at an early
stage. Sung et al. (2009) constructed bifunctional cobalt ferrite
magnetic nanoparticles coated with a silica shell. Rhodamine
B isothiocyanate was incorporated into the silica shell, and the
surface of the nanoparticles was modified with PEG. These
nanoparticles could be efficiently internalized into stem cells,
which then allow for the detection of the cells in vitro and in vivo,
and the non-invasive demarcation of the cells by both optical
imaging and magnetic resonance imaging (MRI). Park et al.
(2014) described a multi-modal (MRI/optical) transfection agent
(MTA) based on monodisperse magnetic nanoparticles for stem
cell gene delivery and tracking. Stem cells after transplantation
were successfully visualized via MRI and optical imaging over a
14-day period. Vuu et al. (2005) also fabricated a gadolinium-
rhodamine nanoparticle for use in labeling and tracking cells via
MRI and optical imaging. This nanoparticle could be modified
with different fluorophores and targeting agents for studying its
trafficking pathways in metastatic cells stem cells, and immune
cells. These nanotechnology-based methods for CSCs labeling
may possibly also be applied for detecting BCSCs in solid breast
cancer tumors (Chen et al., 2016).
Nanoparticles and Nanotubes for
Mediating Thermal Therapy
Thermal therapy is an evolving and growing treatment option
for breast cancer patients. Biologics and chemotherapeutics rely
heavily on the inhibition of a particular molecular pathway,
which can limit the number of responsive patients and give
rise to the development of resistant cancer cells (Narayan
et al., 2009; Korkaya et al., 2012; Paholak et al., 2016). In
comparison, nanoparticle-mediated thermal therapy offers a
broader applicability, including refractory subtypes such as triple
negative breast cancer. Gold-based nanoparticles, iron oxide
nanoparticles and carbon nanotubes have been the predominant
platforms under investigation to produce targeted heat therapy
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against BCSCs in response to a near infrared (NIR) light source,
or in the presence of an alternating magnetic field. (Atkinson
et al., 2010; Burke et al., 2012; Sadhukha et al., 2013; Xu et al.,
2014; Paholak et al., 2016).
Atkinson et al. (2010) applied intravenous injection gold
nanoshells to target BCSCs and mediate hyperthermia. Using
xenograft models of triple-negative breast cancer, they found
that a subpopulation of cancer cells enriched in BCSCs
was more resistant to ionizing radiation than the bulk
tumor cells, and therefore the percentage of BCSCs increased
after radiotreatment. In contrast, they used intravenously
administered, optically activated gold nanoshells to generate
local hyperthermia at 42◦C for 20 min after ionizing radiation,
and observed tumor size reduction without any significant
increase in the relative proportion of BCSCs. Cells derived from
the tumors treated with ionizing radiation plus hyperthermia
exhibited both a marked decrease in tumorigenicity and a more
differentiated phenotype than mock- and ionizing radiation–
treated tumors, which suggested that hyperthermia sensitizes the
BCSCs population to radiation treatment. Xu et al. (2014) found
that gold nanorods (AuNRs)-mediated photothermal therapy
(PTT) selectively eliminated BCSCs in MCF-7 breast cancer
cells. It significantly reduced the ALDH+ cells subpopulation
and the ability of the treated cells to form the mammosphere.
Also, the gene expression of stem cell markers, including ALDH1
and KLF4, was decreased. Cellular uptake assay revealed that
the polyelectrolyte-conjugated AuNRs could be more rapidly
internalized by the BCSCs, and to a greater extent than non-
cancer stem cells, which might be the main reason for the
selective elimination of the BCSCs. There was also the potential
to load salinomycin into the polyelectrolyte-conjugated AuNRs
to obtain a synergistic effect on BCSCs inhibition via NIR light-
triggered drug release and hyperthermia therapy.
Biodegradable and highly crystallized iron oxide nanoparticles
(HCIONPs) were also applied to mediate PTT for effectively
eliminating BCSCs in translational models of triple negative
breast cancer (Paholak et al., 2016). The intravenously injected
HCIONPs (∼15 nm diameter) effectively accumulated in the
breast cancer tumors via the EPR effect, and their highly
crystallized structure enabled effective tumor heating upon
stimulation by NIR light. PTT applied in vitro preferentially
targeted the epithelial-like ALDH+ BCSCs, followed by
mesenchymal-like CD44+/CD24− BCSCs, compared to bulk
cancer cells. The PTT inhibited the capacity of the BCSC for
self-renewal through reduction of mammosphere formation in
primary and secondary generations. Implantation of HCIONPs
in NOD/SCID mice allowed the PTT to effectively impede BCSC-
driven tumor formation. Further studies on the translational
potential of PTT using metastatic and immune-competent
mouse models showed that the PTT could inhibit BCSCs
significantly, and reduced metastasis to the lung and lymph
nodes.
In another study, superparamagnetic iron oxide nanoparticles
(SPIO NPs) with a magnetite core of 12 nm were applied to
induce magnetic hyperthermia for the selective CSCs inhibition
(Sadhukha et al., 2013). SPIO NPs were placed in an alternating
magnetic field to generate localized heat in lung tumor cells A549
and breast tumor cells MDA-MB-231. Multiple assays in vitro and
in vivo revealed that magnetic hyperthermia markedly reduced
or eliminated the BCSC subpopulation. In contrast, conventional
hyperthermia in water bath had not similar effect.
Carbon nanotubes (CNTs) are also candidate platforms for
mediating thermal therapy against breast cancer. Using a model
of triple-negative BCSCs, Burke et al. (2012) showed that
BCSCs lost their long-term proliferative capacity after nanotube-
mediated thermal therapy. In contrast, the BCSCs were resistant
to conventional hyperthermia and a concomitant increase in
the percentage of these cells was observed. Moreover, use of
nanotube-mediated thermal therapy in vivo promoted complete
regression of tumor and long-term survival of mice bearing
cancer stem cell-driven breast tumors. Mechanistically, the
nanotube-mediated thermal therapy promoted rapid membrane
permeabilization and necrosis of BCSCs. It was suggested that
the nanotube-mediated thermal treatment could simultaneously
eliminate both the differentiated cells and the BCSCs that drove
tumor growth and recurrence.
Nanocarriers for BCSCs-Targeted Drug
Delivery
Various kinds of nanocarriers, including polymeric nanoparticles,
inorganic nanoparticles, liposomes, micelles, and nanogels, have
been explored in recent years for BCSCs-targeted drug delivery.
These delivery platforms effectively improved drug stability
and enabled the controlled release of high concentrations of
multicomponent cargos to breast tumor cells and/or BCSCs.
Here, we summarize and categorize the reported nanomedicines
which have been introduced and evaluated for BCSCs-targeted
drug delivery (Table 2).
Polymeric Nanoparticles
Polymeric nanoparticles (PNPs) are submicron-sized colloidal
particles, and are believed to be the simplest nanomedicine form
of soft-materials (Bobo et al., 2016). An anticancer agent is
adsorbed, encapsulated or conjugated either within or onto the
surface of the PNPs, which are capable of providing a required
dose of the anticancer agent to the tumor site for a sustained
period of time. PNPs with labile surface moieties could be readily
modified and functionalized to impart desirable drug delivery
properties, thereby providing a valuable approach to develop
“magic bullet” strategies to deliver one or more therapeutic agents
to BCSCs (Masood, 2016).
The bortezomib (BTZ) loaded poly(ethylene glycol)-block-
poly(D,L-lactide) (PEG-b-PLA) nanoparticles (NPBTZ) was
prepared to enhance the water solubility and stability of BTZ and
to promote anticancer effect (Shen et al., 2015). NPBTZ effectively
delivered BTZ into both BCSCs and non-CSCs, resulting in
proliferation inhibition and initiation of apoptosis. Delivery via
the nanoparticles increased BTZ uptake into both adherent cells
and mammosphere cells and adversely affected the ‘stemness’ of
BCSCs compared with free BTZ. Prolonged circulation half-life
of BTZ and enhanced drug accumulation within the tumor
tissue were also observed. Li et al. (2015) encapsulated decitabine
(DAC) in PEG-b-PLA nanoparticles to sensitize both BCSCs and
non-CSCs to the chemotherapy. According to the in vitro data,
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TABLE 2 | Nanocarriers for BCSCs-targeted drug delivery.
Delivery systems Therapeutic agents Targeting moieties Mechanisms of action Reference
PEG-b-PLA nanoparticles Bortezomib Increased drug accumulation within cancer
cells
Shen et al., 2015
PEG-b-PLA nanoparticles Decitabine/doxorubicin Combination of drugs for sensitizing
BCSCs to chemotherapy
Li et al., 2015
PEG-b-PLA nanoparticles All-trans-retinoic
acid/doxorubicin
Co-delivery of drugs for inducing BCSCs to
differentiate into non-CSCs and inhibiting
tumor cell
Sun et al., 2015
PEG-b-PLA nanoparticles Chloroquine/doxorubicin/
docetaxel
Co-delivery of drugs for sensitizing BCSCs
to chemotherapy
Sun et al., 2016
PLGA nanoparticles Salinomycin/paclitaxel Hyaluronic acid Co-delivery of drugs targeted toward
BCSCs and bulk breast cancer cells
Muntimadugu et al.,
2016
PLGA nanoparticles Paclitaxel Anti-CD133
monoclonal antibody
Selective inhibition of BCSCs Swaminathan et al.,
2013
iTEP nanoparticles Salinomycin Increased drug accumulation within cancer
cells
Zhao et al., 2014
Chitosan modified Pluronic
F127 nanoparticles
Doxorubicin Chitosan Selective inhibition of BCSCs Rao et al., 2015
Cationic lipid-assisted
polymeric nanoparticles
siRNA Increased accumulation of siRNA within
cancer cells
Zuo et al., 2016
HA based self-assembled
nanosystems
siRNA Hyaluronic acid Increased accumulation of siRNA within
cancer cells
Ganesh et al., 2013
Gold nanoparticles Doxorubicin Increased accumulation of drug within
BCSCs
Sun et al., 2014
Iron oxide magnetic
nanoparticles






8-hydroxyquinoline/docetaxel Hyaluronan Combination therapy Wang et al., 2013
Zinc sulfide nanoparticles Selective inhibition of BCSCs Tran et al., 2016
PEG-b-PCL micelles Paclitaxel/salinomycin Octreotide Combination therapy Zhang et al., 2012
PLGA-co-PEG micelles Paclitaxel Anti-CD44 antibody Selective inhibition of BCSCs Gener et al., 2015
PEG-PAC and PEG-PUC
mixture micelles
Thioridazine/doxorubicin Co-delivery of drugs targeted toward
BCSCs and bulk breast cancer cells
Ke et al., 2014
Phospholipid nanomicelles Curcumin Vasoactive intestinal
peptide
Selective inhibition of BCSCs Gülçür et al., 2013
Inorganic calcium and
phosphate ions coated micelles
Curcumin/paclitaxel Hyaluronan
oligosaccharides
Co-delivery of drugs targeted toward
BCSCs
Chen et al., 2015
Cross-linked multilamellar
liposomal vesicles
Salinomycin/doxorubicin Co-delivery of drugs targeted toward
BCSCs and bulk breast cancer cells
Kim et al., 2015
Liposomes Dexamethasone/ESC8/NRP-1
shRNA-encoded plasmid
Co-delivery of drugs and shRNA-encoded
plasmid
Ahmad et al., 2016
Stealth liposomes All-trans retinoic
acid/vinorelbine
Prolonged circulation, improved
biodistribution and accumulation of drugs
within tumors
Li et al., 2011
Stealth liposomes Vinorelbine/parthenolide Prolonged circulation, improved
biodistribution and accumulation of drugs
within cancer cells
Liu et al., 2008
Nanogels Etoposide/salinomycin/
curcumin
Hyaluronic acid Increased accumulation of drug within
cancer cells
Wei et al., 2013
treatment with DAC loaded nanoparticles (NPDAC) combined
with doxorubicin loaded nanoparticles (NPDOX) better reduced
the percentage of BCSCs in the mammospheres of MDA-MB-231
cells and overcame the drug resistance more effectively. The
expression of DNMT1 and DNMT3b was revealed to be
significantly downregulated with the treatment of NPDAC in a
MB-MDA-231 xenograft model and the expression of caspase-9
was induced to increase, which contributed to the increased
susceptibility of BCSCs and bulk cancer cells to NPDOX.
The combination treatment of NPDAC and NPDOX resulted
in the decreased proportion of ALDHhi BCSCs, increased
proportion of apoptotic tumor cells, and the suppression
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of breast cancer cell growth. Sun et al. (2015) encapsulated
doxorubicin (DOX) and all-trans-retinoic acid (ATRA) in the
same PEG-b-PLA nanoparticles on the basis that ATRA could
induce the differentiation of BCSCs, which then reduced their
tumor initiating ability and increased their sensitivity to DOX.
The encapsulated ATRA and DOX both presented with slower
in vitro release profiles compared to free drugs. Compared to
NPDOX, NPATRA and NPATRA-NPDOX mixture, the NPATRA/DOX
co-delivery systems was superior, both in vitro and in vivo, in
suppressing tumor growth. Post-treatment, the BCSCs were
induced to differentiate into non-CSCs and tumor cell growth
was inhibited without triggering BCSCs enrichment. The
prolonged circulation half-lives, improved pharmacokinetics
and increased tumor uptake were added advantages of this
dual drug-loaded nanoparticles system. The same group (Sun
et al., 2016) then investigated the role of autophagy inhibition
in influencing the susceptibility of BCSCs to chemotherapeutics.
Chloroquine (CQ)-mediated autophagy inhibition was showed
to reduce ‘stemness’ and increase sensitivity of sorted ALDHhi
cells to chemotherapeutics (DOX and docetaxel, DTXL) in
breast cancer cell MDA-MB-231, and the effects were further
promoted by the PEG-b-PLA nanoparticle-based delivery
system in vitro. Prolonged circulation half-life and enhanced
accumulation of the drugs within the tumor tissues and ALDHhi
cells were observed in vivo. The combined NPCQ/NPDOX
(NPCQ and NPDOX mixture) and NPCQ/DOX (NPCQ/DOX
co-delivery systems) treatments showed augmented tumor
growth inhibitory effect by killing both the BCSCs and bulk
tumor cells in the MDA-MB-231 orthotopic tumor murine
model.
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles were
designed for co-delivering SAL and PTX to breast cancer
cells with SAL targeted toward BCSCs whereas PTX was used
to kill all cancer cells (Muntimadugu et al., 2016). Active
targeting of BCSCs was achieved through incorporation of
HA onto the surface of the SAL-loaded nanoparticles. In vitro
cytotoxicity studies revealed that combination of HA-coated
SAL nanoparticles and PTX nanoparticles were more potent
than all other formulations. The synergistic action of SAL and
PTX, and their specificity toward the targeted cells, resulted in
high cytotoxicity against the CD44+ breast cancer stem-like
cells. In another study, PTX-loaded PLGA nanocarriers were
conjugated with an anti-CD133 monoclonal antibody to target
the CD133 marker on BCSCs (Swaminathan et al., 2013). In vitro
experiments showed that the PTX-loaded CD133NPs effectively
decreased the number of mammospheres and colonies formed,
while free PTX could not eliminated BCSCs efficiently. In the
MDA-MB-231 xenograft model, free PTX treatment induced
tumor regrowth, which was avoided when PTX CD133NPs were
utilized, suggesting that the encapsulation of PTX in CD133NPs
could significantly decrease the BCSCs and improve therapeutic
efficacy.
A kind of hydrophilic, immune-tolerant, elastin-like
polypeptide (iTEP) was used to develop nanoparticles for
the delivery of SAL to BCSCs in breast tumors (Zhao et al.,
2014). To construct this nanoparticle system, hydrophobic
SAL was conjugated to iTEP; the amphiphilic iTEP-SAL
conjugates self-assemble into nanoparticles, and free SAL
was encapsulated into the nanoparticles with two additives,
N,N-dimethylhexylamine (DMHA) and α-tocopherol. The
dual-encapsulation technique significantly improved the drug
loading efficiency and release profile, plasma drug concentration-
time area under curve and tumor accumulation of SAL,
which led to a boost of BCSCs-elimination effect, which
translated to a delay in tumor growth in vivo. Post-treated 4T1
orthotopic tumors showed a mean BCSCs frequency of 55.62%,
a significant reduction from the mean frequencies of 75.00%
for untreated tumors, and 64.32% for tumors treated with free
SAL.
Rao et al. (2015) developed a DOX-encapsulated polymeric
nanoparticle synthesized using Pluronic F127 cross-linked and
surface-decorated with chitosan that can specifically target the
CD44 receptors of cancer cells. This nanoparticle system was
engineered to release the DOX in acidic environments, which
occurs when the nanoparticles were localized in the acidic tumor
microenvironment and in the cellular endosomes/lysosomes.
This delivery system increased the efficacy of DOX by six
times for eliminating CD44+ breast cancer stem-like cells
compared with free DOX. In orthotopic xenograft tumor
model, these nanoparticles also reduced the size of tumors
efficiently.
Inorganic Nanoparticles
Inorganic nanoparticles include a large number of inorganic
platforms (e.g., metallic, metal oxide and silica nanoparticles),
which could be applied as the drug carriers or as the therapeutic
agents (Bobo et al., 2016).
Sun et al. (2014) developed DOX-tethered gold nanoparticles
to mediate DOX delivery to BCSCs. This system was found to be
highly potent, reducing the BCSC mammosphere formation and
cancer initiation activities, and eliciting marked enhancement in
tumor growth inhibition in murine models. By evading the P-gp
eﬄux pump, these DOX-Hyd@AuNPs nanoparticles were able
to overcome the intrinsic resistance to deliver more DOX into
the BCSCs. The nanoparticles also markedly attenuated tumor
growth during the off-therapy stage by reducing the number of
BCSCs in tumors, in contrast with the therapy with DOX alone,
which evoked an enrichment of BCSCs.
Gemcitabine derivatives loaded iron oxide magnetic
nanoparticles with anti-CD44 antibody modification were
constructed for the selective treatment of CD44-positive cancer
cells (Aires et al., 2016). This nanoparticle delivery system was
able to target different CD44-positive cancer cell lines, and to
selectively kill CD44-positive cancer cells present in pancreatic
and breast cancer cell lines.
Wang et al. (2013) developed 8-hydroxyquinoline (8-HQ)-
loaded hyaluronan modified MSN-supported lipid bilayers (HA-
MSS) and DTXL-loaded MSS to achieve the goal of both targeting
BCSCs and bulk breast cancer cells. It was demonstrated that HA
promoted the uptake of HA-MSS in CD44-overexpressing MCF-
7 mammospheres consisting of bulk cells and BCSCs, revealing
the mechanism of receptor-mediated endocytosis. DTXL or
DTXL-loaded MSS showed much enhanced cytotoxicity against
MCF-7 cells than against MCF-7 mammospheres, whereas 8-HQ
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or 8-HQ-loaded HA-MSS showed much enhanced cytotoxicity
against MCF-7 BCSCs compared with MCF-7 cells. When
applied against the MCF-7 xenografts in mice, the combination
therapy with DTXL-loaded MSS plus 8-HQ-loaded HA-MSS
produced the strongest antitumor efficacy, with little systemic
toxicity in mice.
Zinc sulfide (ZnS) nanoparticles were reported to possess
inhibitory effects toward the migration and invasion of
BCSCs in MCF-7-SC with no apparent cytotoxicity up to a
concentration of 400 µg/mL (Tran et al., 2016). The ZnS
nanoparticles significantly inhibited the wound healing in the
MCF-7-SC cells. The results suggested that ZnS nanoparticles
inhibited the metastasis of MCF-7-SCs in a dose-dependent
manner by suppressing the epithelial-mesenchymal transition
process.
Polymeric Micelles
Polymeric micelles are derived from self-assembled amphiphilic
block copolymers. Therefore these colloidal particles contain
both hydrophilic and hydrophobic components, which provide
platforms for various modifications to improve targeting
efficiency. Polymeric micelles have been popular drug carriers
for anticancer treatment due to their uniformity, small sizes,
and prolonged circulation time (Torchilin, 2007; Jeong et al.,
2016).
Zhang et al. (2012) prepared PEG-b-PCL polymeric micelles
modified with octreotide (Oct) and loaded with PTX (Oct-M-
PTX) as well as PEG-b-PCL polymeric micelles loaded with
SAL (M-SAL) using the thin film hydration method. Oct
was coupled to the PEG end of PEG-b-PCL before micelles
preparing for the specific targeting toward somatostatin receptors
(SSTR) overexpressed in breast cancer. It was observed that the
uptake of Oct modified micelles was significantly promoted in
SSTR overexpressed MCF-7 cells while the promotion could
be inhibited by free Oct, confirming the receptor-mediated
endocytosis mechanism. M-SAL was capable of decreasing the
proportion of BCSCs. Oct-M-PTX exhibited stronger inhibitory
action against the MCF-7 cells compared with PTX-loaded
micelles (M-PTX), and synergistic effect was found when Oct-
M-PTX and M-SAL were utilized in combination. Similar
synergistic effect was also observed in the MCF-7 xenografts.
In vivo studies revealed that M-SAL was more effective in
inhibiting BCSCs compared with free SAL. In another study,
PTX loaded and anti-CD44 antibodies functionalized PLGA-
co-PEG polymeric micelles were prepared for treatment against
breast cancer cell lines (Gener et al., 2015). The results showed
that the encapsulation of PTX into the targeted PLGA-co-
PEG micelles increased sensitivity of BCSCs to PTX. Ke et al.
(2014) utilized a mixture of acid-functionalized poly(carbonate)
and poly(ethylene glycol) diblock copolymer (PEG-PAC) and
urea-functionalized poly(carbonate) (PUC) and PEG diblock
copolymer (PEG-PUC) to form micelles via self-assembly. These
mixed micelles (MM) were applied to co-deliver thioridazine
(THZ) and DOX targeting both breast cancer cells and BCSCs.
THZ and THZ-MM were effective in inhibiting BCSCs, while
DOX was efficient in suppressing non-stem-like cancer cells. Co-
delivery of free THZ and DOX or THZ-MM and DOX-MM
resulted in a stronger inhibitory effect on BCSCs, as compared
with free DOX or DOX-MM alone. THZ and THZ-MM were
capable of lowering the population of BCSCs in unsorted cells. In
the BT-474 xenografts, the co-delivery of DOX-MM and THZ-
MM produced the strongest antitumor efficacy, and both THZ
and THZ-MM showed strong activity against BCSCs. Gülçür
et al. (2013) investigated the potential of using curcumin (CUR)-
loaded sterically stabilized phospholipid nanomicelles (C-SSM)
surface conjugated with VIP (C-SSM-VIP) to target and hinder
breast cancer with BCSCs. The in vitro experiments revealed that
the nanomicellar C-SSM-VIP resulted in up to 20% inhibition of
tumorsphere formation at a dose of 5 µM of curcumin.
More complex polymeric micellar delivery systems have been
constructed. For example, a multifunctional oligosaccharides
of hyaluronan (oHA) conjugates, oHA-histidine-menthone 1,2-
glycerol ketal (oHM) was prepared to form micelles carriers
for BCSCs targeting (Chen et al., 2015). The oHM conjugates
possessed the oHA to target the CD44 receptor, and these
conjugates self-assembled into micelles. CUR and PTX were
loaded into the oHM micelles. Novel “nano-eggs” were
then fabricated through controlled deposition of inorganic
calcium and phosphate ions onto the surface of the micelles
via a sequential addition method. The size of nano-eggs
(120.6 ± 4.5 nm) was smaller than that of oHM micelles
(158.6 ± 6.4 nm), indicating that the micelles might be
compacted by mineralization. The “nano-eggs” were stable at
pH 7.4, while in acidic conditions (pH 6.5), the inorganic
minerals outer shells were destroyed. The loaded CUR and PTX
were released in a sustained manner from both the nano-eggs
and oHM micelles depending on the solution pH. In vivo, the
nano-eggs showed stronger tumor targeting effects than the
oHM micelles. The antitumor efficacy against MDA-MB-231
xenografts in nude mice revealed that the co-delivery of PTX
and CUR via the nano-eggs produced the strongest antitumor
efficacy, with the nano-eggs showing strong activity against the
BCSCs.
Liposomes
Liposomes are colloidal nanocarriers consisting of amphiphilic
phospholipid bilayers, which can be loaded with both hydrophilic
and hydrophobic drugs. Liposomes are ideal nanocarriers for
anti-BCSCs therapies owing to their desirable characteristics such
as biocompatibility, ease of surface modification, and long blood
circulation time (Jeong et al., 2016).
All-trans-retinoic acid (ATRA) stealth liposomes have been
studied for their ability to prevent the relapse of breast cancer
arising from BCSCs, and as co-therapy with a cytotoxic agent
for treating breast cancer (Li et al., 2011). Stealth property
was imparted to the liposomes by modification with PEG
derivative. Efficacies of action were confirmed in vitro and in
t BCSCs xenografts in NOD/SCID mice. The ATRA stealth
liposomes were shown to prevent the relapse of breast cancer
by promoting BCSCs differentiation and arresting the cell-cycle.
They could also be used to treat breast cancer in combination
with vinorelbine stealth liposomes (Li et al., 2011). In another
study, vinorelbine stealth liposomes and parthenolide stealth
liposomes given as a combination were shown to provide
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synergistic pharmacological properties to inhibit the proliferation
of BCSCs and non-stem cancer cells in the MCF-7 and MDA-
MB-231 cell models (Liu et al., 2008). A more robust inhibitory
effect on the BCSCs was observed with the combination
treatment than treatment with vinorelbine alone. In the MCF-7
xenografts, the combination treatment produced a full inhibitory
effect.
Nanogels
Nanogels, which are hydrogel materials confined to nanoscopic
dimensions, are being explored as drug delivery agents for
targeting cancer due to their easy tailoring properties. They can
also efficiently encapsulate diverse therapeutics through simple
fabrication mechanisms (Soni and Yadav, 2016).
Based on cholesteryl-HA (CHA), nanogel-drug conjugates
were synthesized to target and inhibit drug-resistant tumors (Wei
et al., 2013). Some poorly soluble drugs with activity against
CSCs, such as SAL, CUR, and etoposide (ETO), had undesirable
bioavailability, which could be significantly ameliorated by
the conjugates. Small nanogel particles were formed by
ultrasonication. Following the hydrolysis of biodegradable ester
linkages, drugs were released from nanogels in a sustained
manner. The suppression of CD44-expressing drug-resistant
human breast and pancreatic adenocarcinoma cells by CHA-
drug nanogels was 2–7 times more effective than that by free
drugs or non-modified HA-drug conjugates. Via CD44 receptor-
mediated endocytosis, the nanogels were internalized efficiently
and interacted with the cancer cell membrane simultaneously.
CHA-drug nanogels could be anchored by cholesterol moieties in
the cellular membrane after unfolding, which evidently resulted
in more drug accumulation in the cancer cells compared with
HA-drug conjugates without cholesteryl modification. CHA-
drug nanogels penetrated multicellular cancer spheroids more
efficiently and displayed stronger inhibitory effects in the system
modeling tumor environment than both HA-drug conjugates and
free drugs.
Nanocarriers for siRNA Delivery
RNA interference (RNAi) has emerged as a powerful strategy
for BCSCs therapy by selective down-regulation of key genes.
However, the delivery of small interfering RNAs (siRNAs) to
specific tumor tissues and cells is a major hurdle that remains
to be addressed before this experimental technique can become a
clinically viable therapeutic option (Ganesh et al., 2013). Systemic
siRNA delivery systems should have properties that include
biocompatibility, biodegradability, and non-immunogenicity.
Additionally, the systems should protect the siRNA load from
serum nucleases, and provide effective targeted delivery that
includes a mechanism for siRNA endosomal escape to enter the
RNAi machinery and activate RNAi pathways (Xu and Wang,
2015).
To develop an effective siRNA delivery system for anti-
BCSCs therapy, Zuo et al. (2016) constructed cationic lipid-
assisted polymeric nanoparticles encapsulated with siRNA via a
double emulsion method. The nanoparticles loaded with siRNA
targeting the oncogene polo-like kinase 1 (Plk1) effectively
eliminated the BCSCs in vitro. However, the BCSCs in the
residual tumor tissue became enriched following systemic
treatment. LY364947, an inhibitor of TGF-b type I receptor, could
inhibit the TGF-b signaling pathway, and therefore promoted
the penetration of nanoparticles in the tumor tissue. With the
help of TGF-b signaling pathway inhibition, the intratumoral
distribution of nanoparticles in the MDA-MB-231 xenografts
was significantly ameliorated and the therapeutic siRNA was
successfully delivered to the BCSCs in vivo. LY364947 altered
the tumor microenvironment and improved the EPR effect,
thereby ultimately improved in vivo transfection efficiency of
BCSCs.
Ganesh et al. (2013) prepared and screened a series of
HA based self-assembling nanosystems for targeted delivery
of siRNA. Polyamines and lipids of varying carbon chain
lengths/nitrogen content were utilized to functionalize the HA
polymers. Nanosystems derived from many HA derivatives
transfected siRNA efficiently into CD44 overexpressing cancer
cells including MDA-MB468 breast cancer cells. These siRNA
encapsulated nanosystems selectively accumulated at tumor site
and targeted specific gene knock down in both solid tumors
and metastatic tumors in vivo. These HA based siRNA delivery
systems thus portend to be promising for systemic targeted
therapeutics against CD44 overexpressing breast cancer stem-like
cells and metastatic lesions.
CONCLUSION AND PROSPECTS
Nanomedicines seem to be efficient candidates for BCSCs
therapy. Multifunctional nanomedicines offer a range of
strategies for targeting one or more therapeutics to BCSCs,
increasing their cellular uptake, prolonging systemic circulation,
improving biodistribution profiles, and resolving problems
of poor stability and solubility. However, the application of
technology-based anti-BCSCs therapeutics is in a relatively early
stage. To advance these nanotechnologies for anti-BCSCs clinical
therapy, more efforts are needed. Firstly, a better understanding
of BCSCs microenvironment biology and key characteristics
is necessary for the fabrication of more effective anti-BCSCs
delivery systems. Additional genetic/molecular markers that are
more specific to BCSCs may have to be identified to optimize
the active BCSCs targeting strategies. Intelligent delivery systems
could be designed that incorporate a BCSCs niche sensitive
triggered drug release strategy. Secondly, mechanisms involved
in the epigenetic regulation of BCSC self-renewal and non-
BCSC reprogramming needs to be thoroughly understood.
Based on these understandings, more effective chemo- or gene
therapies, as well as better delivery systems, are likely to be
designed and constructed. Thirdly, comprehensive therapeutic
systems affecting both BCSCs and bulk breast cancer cells are
needed. A successful therapy will encompass the prevention
of breast cancer initiation, progression, resistance, recurrence,
and metastasis. According to the CSCs theory, BCSCs and
differentiated breast cancer cells may transform into each
other via unknown pathway(s). Therapies that kill only the
BCSCs or breast cancer cells could possibly cause recurrence.
Synergistic delivery systems that eliminate BCSCs and
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non-BCSCs simultaneously will be preferred. Aside from BCSC
biology, the unsatisfactory stability of nanomedicines and
associated potential for leakage of loaded drugs during blood
circulation are concerns that are yet to be resolved. Strategies
such as surface modification or coating are needed, and more
basic and applied researches in vivo are necessary. In summary,
nanotechnology based BCSCs targeting treatment provides an
attractive strategy for therapy of breast cancers. Although a
concerted effort is required to tackle the challenges outlined
above, there is great optimism that the near future will see
successful clinical translation of BCSCs-targeted nanomedicines
to provide unique benefit for cancer patients.
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